Viska Bio
Supplier
Summarized by Halo AI
Viska Bio develops targeted therapies for cancer that induce immunogenic cell death, using an antibody/fusion-protein approach to deliver activity to EGFR-expressing tumor cells.
Company size
Less than 500 employees
Portfolio summary
Early-stage immunotherapy platform focused on localized immunogenic cell death for cancer treatment and prevention
R&D locations
Cambridge, Massachusetts, United States
Viska Bio is developing cancer therapies aimed at inducing immunogenic cell death. Its approach uses a fusion protein with targeted delivery to EGFR-expressing cancer cells, with a primary program in glioblastoma and stated plans for IND-enabling studies in late 2025. The company also describes a platform concept that can be adapted to other diseases by exchanging the antibody target.
AI summary generated on Jun 22, 2026
OpenAlex
OpenAlexFor general inquiries
EF
Eric Fossel
CEO
Is this page yours? Boost its visibility
List technologies, facilities, services, or grant collaboration opportunities.
Partner smarter. Move faster.
Get new partnering requests
delivered to your inbox.
delivered to your inbox.
© 2026 Halo Cures, Inc.